Eisai CoESALF 74 Net Current Asset Value is $4.73 as of Mar. 2026, which is 67% below its 10-year median of 14.30. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $35.73 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 612 Drug Manufacturers companies, Eisai Co ranks worse than 50.82% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Eisai Co's net current asset value per share for the quarter that ended in Mar. 2026 was $4.73.
The historical rank and industry rank for Eisai Co's Net Current Asset Value or its related term are showing as below:
ESALF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.32 Med: 14.3 Max: 43.37
Current: 5.32
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Eisai Co was 43.37. The lowest was 5.32. And the median was 14.30.
ESALF's Price-to-Net-Current-Asset-Value is ranked worse than 50.82% of 612
companies
in the Drug Manufacturers industry
Industry Median: 5.47
vs ESALF: 5.32
Eisai Co (OTCPK:ESALF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Eisai Co Net Current Asset Value Related Terms
Eisai Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Eisai Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESALF vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Eisai Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $4.73 mean?
Eisai Co (ESALF) has a Net Current Asset Value of $4.73 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Eisai Co and its competitors. This is 67% below median its historical median of 14.30. Over the past decade, Eisai Co's Net Current Asset Value has ranged from 5.32 to 43.37. According to the industry distribution chart, Eisai Co ranks #311 out of 612 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Eisai Co's Net Current Asset Value too high?
Eisai Co's current Net Current Asset Value of $4.73 is 67% below median its 10-year median of 14.30. Over the past 10 years, this metric has ranged from a low of 5.32 to a high of 43.37. The Drug Manufacturers industry median Net Current Asset Value is 5.47. Eisai Co's value of $4.73 is 13.5% below this industry median. Based on the distribution chart, Eisai Co ranks #311 out of 612 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #311 out of 612 companies for Net Current Asset Value. This places Eisai Co in the lower half of its industry. The industry median Net Current Asset Value is 5.47. Eisai Co's value of $4.73 is 13.5% below this benchmark. Historically, Eisai Co's own Net Current Asset Value has ranged from 5.32 to 43.37 over the past decade. While the company's 10-year median is 14.30 vs. the industry median of 5.47, Eisai Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.47, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current Net Current Asset Value of $4.73 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Net Current Asset Value is $4.73, which is 67% below median its own 10-year median of 14.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.73, compared to a current price of $25.00 — trading 30% below its estimated fair value. The current Net Current Asset Value is $4.73, which is 67% below median its 10-year median of 14.30 and 13.5% below the Drug Manufacturers industry median of 5.47. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Eisai Co (ESALF), the current Net Current Asset Value is $4.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 30% below its estimated GF Value™ of $35.73.
GuruFocus considers Eisai Co to be Significantly Undervalued.
Key valuation signals for ESALF:
Net Current Asset Value: $4.73 (67% below median its 10-year median of 14.30)
GF Value™: $35.73 vs. price of $25.00 (30% below fair value)
Industry Position: 13.5% below the Drug Manufacturers median (#311 of 612)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score
Get the complete analysis for ESALF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
